Infant Bacterial Therapeutics
80 SEK +3.9%Be the first to follow this company
Infant Bacterial Therapeutics, also known by the name IBT, is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market. The company's head office is located in Stockholm.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IBT B
Daily low / high price
76.2 / 80
SEK
Market cap
1.08B SEK
Turnover
121.33K SEK
Volume
1.6K
Financial calendar
Interim report
2024-05-07
General meeting
2024-05-08
Interim report
2024-08-28
Interim report
2024-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
SIX SIS AG, W8IMY | 11.0 % | 8.4 % |
Fjärde AP-fonden | 10.0 % | 7.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Infant Bacterial Therapeutics AB publishes the Annual Report for 2023
Infant Bacterial Therapeutics AB (publ), Interim report January 1-December 31, 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools